VIRAL HEPATITIS
Clinical trials for VIRAL HEPATITIS explained in plain language.
Never miss a new study
Get alerted when new VIRAL HEPATITIS trials appear
Sign up with your email to follow new studies for VIRAL HEPATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to tackle stubborn hepatitis d
Disease control OngoingThis Phase 3 trial tests whether a combination of two drugs, tobevibart and elebsiran, can suppress hepatitis D virus in adults who are still infected despite taking bulevirtide. About 150 participants will receive the combo as injections. The main goal is to see if the virus bec…
Matched conditions: VIRAL HEPATITIS
Phase: PHASE3 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug duo aims to control hard-to-treat hepatitis delta
Disease control OngoingThis phase 3 study tests whether a combination of two drugs, tobevibart and elebsiran, can control chronic hepatitis delta better than waiting for treatment. About 124 adults with the infection will receive either the combo therapy or delayed treatment. The goal is to see if the …
Matched conditions: VIRAL HEPATITIS
Phase: PHASE3 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug duo takes on rare liver virus in head-to-head trial
Disease control OngoingThis study tests whether a combination of two experimental drugs (Tobevibart and Elebsiran) works better than the current treatment Bulevirtide for people with chronic hepatitis D, a serious liver infection. About 100 adults with stable liver disease will receive either the combo…
Matched conditions: VIRAL HEPATITIS
Phase: PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC